Released Nov 1, 2017, after the close
10-Q filed Nov 1, 2017, 32 days after period end · 0001564590-17-020777
Q3 2017 · 10-Q
Revenue$1.03M$1.03M ±0.0% vs Q3 2016±0.0% vs Q2 2017
Net Income-$10.68M-$10.68M N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.26-$0.26 N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$10,340,000N/M
Operating Cash Flowderived-$9,769,000N/M
Free Cash Flowderived-$10,131,000N/M
Margins · derived
Operating margin-1007.8%−190.2 pt vs Q3 2016
Net margin-1041.3%−189.8 pt vs Q3 2016
What the release said
The release
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | $1.03M | — |
| Net Income | -$10.68M | -$8.74M | -$6.89M | -$6.60M |
| EPS Diluted | -$0.26 | -$0.27 | -$0.24 | -$0.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR